Category: Kinase Inhibitor Library

MicroRNAs are a class of short, highly conserved, non-coding RNAs that function as negative posttranscriptional regulators of target genes. Accumulating evidence has shown that miRNAs are aberrantly expressed during the development and/or progression of a variety of human cancers. Roles for miRNAs in the regulation of tumorigenesis via the targeting of important genes within signaling pathways are evident. To date, however, miRNAs that target FHL1 have not been reported. To clarify the mechanism of FHL1 downregulation during tumorogenesis, we assessed the involvement of miRNAs that target the FHL1 promoter. We report that Torin 1 miR-410 is upregulated in colorectal cancer and hepatocarcinoma and that miR-410 can decrease FHL1 protein levels both directly by targeting the FHL1 3’UTR and indirectly by promoting the upregulation of DNA methylases. In particular, miR-410 promotes the binding of DNMT3A to the FHL1 promoter, which leads to the hypermethylation of the FHL1 promoter. The findings here could provide a mechanism for FHL1 down-regulation during tumorigenesis. Consistently, analysis of clinical hepatocarcinoma and colorectal specimens revealed a physiological association between the expression of miR-410, FHL1 and DNMT3A, which implicates miR-410 as a potential oncogenic biomarker that functions by down-regulating FHL1 in these tissues. The findings here within indicate, for the first time, that miR410 may serve as a regulator of FHL1 expression through direct targeting of its 3’UTR and indirect regulation of its methylation in human colorectal cancer and hepatocarcinoma. Recent reports have shown other possible functions of miR-410. miR410 is involved in the regulation of lipoprotein lipase levels, muscle regeneration, and idiopathic pulmonary fibrosis. Also, miR-410 is considered a diagnostic and prognostic biomarker in some diseases. In a study based on plasma samples from 122 women, tumor tissues with a combination of miR-92a/miR-410 or miR-92a/miR-205/miR-410 expression was shown to serve as a noninvasive biomarker for early cancer detection and prognosis. Therefore, there is a precedent for a possible role of miR-410 as a biomarker for malignant diseases. Our results also show that expression is elevated in clinical tissue from colorectal and liver tumors; however, based on our limited sample size, the use of a larger sample size may be required to confirm the potential utility of miR-410 as a biomarker for colorectal and liver tumors. FHL1 is a well known tumor-suppressor gene with no or relatively low expression in tumors. Methylation-silenced mutation is one of the important mechanisms contributing its low-expression. Here, we have shown another new mechanism for silencing of FHL1 expression in tumors: miR-410 not only specifically targets the 39UTR of FHL1, but also promotes DNMT3A binding to the FHL1 promoter, which leads to its hypermethylation in cancer cells, suggesting that the regulation of FHL1 by miR-410 occurs by dual mechanisms. Exogenous miR-410 expression leads to the upregulation of methylases, and both miR-410 and DNMT3A are upregulated.

Critically appraise relevant research, and to collect and analyse data from the studies that are included in the review. Statistical methods may or may not be used to analyse and summarise the results of the included studies “. Systematic reviews are increasingly accepted as important evidence-based decision-making aids. However, decision-makers cite the lack of equity considerations as barriers to using systematic reviews. The lack of analysis and lack of reporting of evidence about sex/gender in systematic reviews raise scientific and ethical concerns. Barriers to implementing sex/gender analysis in systematic reviews are manifold. Evidence suggests that there is a general lack of understanding of the concepts of sex and gender, how they are interrelated, whether and how they affect health interventions. Other barriers include: limited access to sexdisaggregated data, issues with data quality and reporting, challenges related to measuring and analysing gender and, a lack of guidance on methods.

More recently, however, because many funding agencies now have policies mandating that both men and women be included in clinical trials and that results for men and women be reported and interpreted separately, more researchers have begun to conduct sex/gender analysis. Systematic reviewers, most notably those working within the Cochrane Collaboration, are also increasingly examining the related question “To whom does this evidence apply?” in their assessment of the quality of available evidence. However, this is an emerging area of inquiry and there continues to be a lack of exemplar reviews that address sex/gender considerations. When reviewers have addressed sex/gender their conclusions have often been contingent on methodological or data limitations. For example, a systematic review of tobacco and smoking cessation interventions found some differences in intervention effects for girls and boys. The authors reported that school-based restrictions may be more effective for girls whereas increases in the price of tobacco products may have more influence on boys; however, these findings were often from single or methodologically weak studies. Further, in a systematic review on quality of life after total hip or total knee arthroplasty, men appeared to benefit more from the intervention but the authors stated that their conclusion was tempered by the few studies that addressed this issue.

A recent meta-analysis of 89 studies using clinical trials, interrupted time series and other methods assessed the effectiveness of antibiotic stewardship programs. It showed that policy interventions changed antibiotic treatment and this was associated with significant improvement in outcomes. Unfortunately, there were hardly any studies from LMIC in this metanalysis. This is an important aspect to consider since infections and irrational antibiotic use are widely prevalent in these countries. Another purpose of antibiotic stewardship is to contain antibiotic use. Containment is important as increased antibiotic use leading to environmental pressure contributes more to bacterial resistance.

DDR is stably associated with the cellular senescence condition. The biology of SAA has been investigated extensively. SAA is a key mediator in innate immune responses, stimulation of cytokines, and matrix metalloproteinases. Biological activities include regulation of cholesterol metabolism, insulin resistance and glycemic control. During acute phase, SAA displaces 80% of ApoAI from HDL. Elevated levels of SAA are down-regulated by therapy with PPARγ agonist agents, whereas glucocorticoid treatment did not Pazopanib downregulate extrahepatic expression of SAA. In chronic inflammatory diseases, such as rheumatoid arthritis, metabolic syndrome or atherosclerosis, prolonged elevation of SAA may contribute to tissue damage and degradation. Elevated SAA contributes to AA amyloidosis if abnormal cleavage and deposition occurs in genetically predisposed individuals. SAA was shown to regulate expression of TGF-β, the master regulator of connective tissue remodeling and fibrogenesis. In mice, SAA adenoviral transfer leads to increased plasma TGF-β, and increased biglycan expression. Interestingly, it has been reported that the SAA receptor FPRL-1/FPR2 was involved in TGF-β, as well as in biglycan expression. These studies implicate SAA in extracellular matrix remodeling. The role of inflammation in SSc, and biomarkers for identifying inflammation, have received scant attention to date. Previous studies showed that erythrocyte sedimentation rate is elevated in SSc and predicts mortality. ESR is one of the parameters comprising the modified Medsger SSc Disease Severity Scale. Levels of CRP are also elevated in SSc, correlate with disease activity and pulmonary function, and predict pulmonary decline and survival. In contrast to CRP and ESR, little is known to date about SAA in SSc or its role in disease pathogenesis. A small pilot study over three decades ago showed elevated SAA levels in 24% of SSc patients; marked elevations predicted poor survival. In the present study, we sought to determine circulating levels of SAA in SSc, and to correlate these levels with clinical features of the disease. Our findings indicate that SAA levels are elevated in a subset of SSc patients, and correlate with pulmonary involvement and patient-reported outcomes, in particular symptoms related to respiratory dysfunction. In vitro, recombinant SAA induced enhanced IL-6 and IL-8 production in fibroblasts explanted from normal human lungs. These findings provide evidence for the occurrence of a systemic inflammatory process in SSc, and suggest a potential for SAA as a biomarker in evaluating patients with SSc. We show here that circulating levels of the inflammatory marker SAA are elevated in patients with SSc. Elevated SAA levels are associated with signs and symptoms of pulmonary involvement, as well as health-related quality of life measures. In particular, levels of SAA were found to correlate with measures of pulmonary function and radiologic evidence of SSc-associated interstitial lung disease. Furthermore, SAA levels were significantly correlated with PA pressure, in a manner analogous to recent findings in patients with idiopathic pulmonary arterial hypertension. Exposure of healthy lung fibroblasts in culture to SAA resulted in stimulation of the expression of IL-6 and IL-8, two cytokines previously implicated in the pathogenesis of SSc. The levels of SAA were only modestly correlated with those of the inflammatory markers CRP and ESR. While levels of CRP and ESR were elevated in 29 and 37% of SSc patients, respectively, the correlation with SAA was less than 0.5, revealing unexpected differences in these three inflammatory parameters in SSc.

Chronic inflammation and fibrosis are often linked, particularly in interstitial lung disease. For instance, in patients with sarcoid lung disease, SAA correlated with collagen deposition and lung fibrosis and negative correlation of lung functions and SAA was found. Recombinant SAA potently stimulated the production of IL-6 and IL-8 in lung fibroblasts in culture. Importantly, these stimulatory effects of SAA on cytokine gene expression occurred at physiologic concentrations of SAA. We previously reported that SAA stimulated IL-6 in human endothelial cells in culture and IL-8, MMP-3 proteins and NF-ƘB DNA binding activity were up-regulated by SAA in fibroblast-like synoviocytes. In this study we report stimulation of IL-6 in lung fibroblasts at the mRNA level and secreted cytokine production. IL-6 is emerging as a potentially important mediator of fibrosis in SSc. In fibroblasts, SAA has been recently shown to trigger a TLR2-dependent innate immune pathway, contributing to induction of IL-6, and potentially linking SAA to innate immunity and fibrosis in SSc. IL-6 is implicated in the regulation of collagen gene expression and extracellular matrix production. Furthermore, levels of IL-6 are elevated in serum and lesional tissue of patients with SSc. Treatment of SSc patients with anti-IL-6 intervention was shown to have beneficial effects in a small clinical trial. IL-8 is a multifunctional chemokine produced primarily by macrophages, and exerting potent effects on chemotaxis and angiogenesis. Scleroderma fibroblasts spontaneously secrete IL-8. We and others have shown that levels of IL-8 are elevated in the serum, as well as in bronchoalveolar lavage fluid, from patients with SSc. The present results demonstrate elevated circulating SAA levels in a subset of SSc patients that are correlated with symptoms and signs of SSc-associated pulmonary involvement. The biological implications of these findings remain to be elucidated. It is noteworthy, however, that in lung fibroblasts, SAA acts as a direct stimulus for the synthesis of IL-6 and IL-8, mediators implicated in the pathogenesis of SSc and its pulmonary complications. Longitudinal studies to determine if baseline SAA levels in SSc predict disease activity or progression, and whether changes in SAA levels over time correlate with changes in measures of disease activity, seem warranted. Nearsightedness arises from a mismatch between the focal power of the optical components and the axial length. It is the most commonly found disorder in the development of the juvenile eye and steadily rises in prevalence, currently affecting 30–50% of young adults in Europe and around 80% in Asia. Recent studies have shown that Trichostatin A outdoor exposure seems to be a promising approach to reduce the development of myopia – children who spend more time outdoors appear to be less likely to become myopic. A number of possible factors can be suggested for the protective effect of outdoor exposure, such as light intensity, physical activity, viewing distance, variations in accommodative requirement, which have been systematically discussed by a recent review. Rose et al. were the first to suggest that light intensity might be an important factor and this assumption has gained accumulating experimental evidence in animals. Specifically, with the urbanization of modern world, humans tend to spend more time indoors with illuminances typically ranging from 100 lux to 500 lux. Compared with the outdoor illuminance, the indoor illuminance is very much lower. Cohen et al., observed that chickens raised at low light for extended periods developed significant myopia, as compared to those reared under standard or high light level.

While the Cochrane Collaboration is a lead producer of systematic reviews internationally, further evaluation and dissemination of the briefing notes throughout the Cochrane Collaboration network and beyond Cochrane is needed to ensure wider representation of systematic review authors. Through wider dissemination and evaluation efforts we hope to engage more members of the systematic review community in the development of methodological and practical guidance to facilitate sex/gender analysis and foster changes in practice. In recent years, a number of investigations evaluating the constituency of oral fluid have discovered that it may actually reflect an individual’s physiological condition. In fact, multiple groups have identified saliva-based proteomic, transcriptomic, and microbiological markers for Sjo¨gren’s syndrome, inflammatory bowel disease, and even cancers. Although promising, the novelty of using saliva as an effective evaluator of local and systemic health has not found widespread acceptance. Significant skepticism remains regarding how these unique molecular indicators are developed in saliva. Exosomes are small, lipid-bound, spherical structures measuring approximately 30 to 100 nm in diameter. Randomly formed from the invagination of intracellular vesicles, exosomes often contain biologically active host cell lipids, proteins, miRNAs, mRNAs, ncRNAs, and other cellular constituents. Microvesicles containing similar host cell biomolecules and heterogeneous in size may also be formed by the budding-off the cellular membrane. Majority of vesicles isolated from body fluids are referred as exosomes based on their exosomal protein markers. However, the microvesicles do be co-isolated using current available purification method. We, therefore, collectively refer these vesicles as exosome-like microvesicles here. ELMs are known to shed continuously from multiple cell types including: hematopoietic, intestinal epithelial, Schwann, fat, neuronal, fibroblasts, and several tumor cell lines. Many types of cancer cells release ELMs and tumor-derived ELMs carry a wide range of nucleic acids, including miRNA, mRNA, ncRNA and DNA. ELMs containing these nucleic acids have been shown to reflect the genetic status of tumor, and be able to travel to distant site and transfer their cargo to the recipient cells and to induce phenotypic changes. Previous investigations have revealed that tumors are often the primary source of circulating membrane vesicles and increased amount of tumor derived protein, RNA and DNA were found in the blood of cancer patients. In addition to their presence in blood, ELMs are also present in urine, saliva, breast milk, malignant and pleural effusions, synovial fluid, epididymal fluid, and amniotic fluid. Therefore, tissue-specific exosomes with their constituent tissue-specific biomarkers can serve as a biomarker source for the diagnosis, prognosis, and monitoring of disease. Recent evidence has emerged describing a role for ELMs in the processes that govern the induction of discriminatory salivary biomarkers. However, the mechanisms underpinning the etiology and biogenesis of saliva-based biomarkers have not been clearly explained. Understanding how these markers come to exist in oral fluids will both shed light on the body’s capacity for extracellular communication and help credential salivary biomarkers as an acceptable mode for Semaxanib VEGFR/PDGFR inhibitor personalized medical assessment.